Related Experiment Video
Updated: Apr 6, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Thrombolytic Therapy Using Urokinase for Management of Central Venous Catheter Thrombosis
Jung Tack Son1, Sun Young Min1, Jae Il Kim1
1Departments of Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Insights
Bedside thrombolysis with urokinase effectively managed central venous catheter (CVC) thrombosis in 75% of patients. This urokinase protocol rarely required reintervention for CVC thrombosis, offering a successful treatment option.
Area of Science:
- Vascular Surgery
- Interventional Radiology
- Critical Care Medicine
Background:
- Management of central venous catheter (CVC) thrombosis protocols vary.
- Efficacy of CVC thrombosis management methods is infrequently reported.
- Investigating effective CVC thrombosis treatments is crucial for patient care.
Purpose of the Study:
- To evaluate the effectiveness of bedside thrombolysis using urokinase for managing CVC thrombosis.
- To determine the success rate of urokinase in recanalizing thrombosed CVCs.
- To assess the need for reintervention after urokinase therapy for CVC thrombosis.
Main Methods:
- Retrospective review of CVC insertions between April 2012 and June 2014.
- Implemented a standardized protocol for CVC management.
- Administered 5,000 U of urokinase directly into thrombosed CVCs.
Main Results:
- Thrombosis occurred in 8.8% of 137 CVCs; infection in 5.8%.
- Urokinase successfully recanalized CVCs in 75% of patients (9/12).
- Peripherally inserted central catheter (PICC) group showed higher recanalization rates (87.5%) than chemoport group (50%).
- Only 2.2% of patients required reintervention for CVC thrombosis with urokinase therapy.
- Independent risk factors for CVC thrombosis included age <60, PICC use, and catheter tip location above the superior vena cava.
Conclusions:
- Bedside thrombolysis with urokinase is an effective treatment for CVC thrombosis.
- Applying a urokinase protocol for CVC thrombosis management significantly reduces the need for reintervention.
Purpose:
The management of central venous catheters (CVCs) and catheter thrombosis vary among centers, and the efficacy of the methods of management of catheter thrombosis in CVCs is rarely reported. We investigated the efficacy of bedside thrombolysis with urokinase for the management of catheter thrombosis.
Materials And Methods:
We retrospectively reviewed data from patients who had undergone CVC insertion by a single surgeon in a single center between April 2012 and June 2014. We used a protocol for the management of CVCs and when catheter thrombosis was confirmed, 5,000 U urokinase was infused into the catheter.
Results:
A total of 137 CVCs were inserted in 126 patients. The most common catheter-related complication was thrombosis (12, 8.8%) followed by infection (8, 5.8%). Nine of the 12 patients (75%) with catheter thrombosis were recanalized successfully with urokinase. The rate of CVC recanalization was higher in the peripherally inserted central catheter (PICC) group (87.5%) than the chemoport group (50%). Reintervention for catheter-related thrombosis was needed in only 2.2% of patients when thrombolytic therapy using urokinase was applied. Age <60 years (P=0.035), PICC group (P=0.037) and location of the catheter tip above the superior vena cava (P=0.044) were confirmed as independent risk factors for catheter thrombosis.
Conclusion:
Thrombolysis therapy using urokinase could successfully manage CVC thrombosis. Reintervention was rarely needed when a protocol using urokinase was applied for the management of CVC thromboses.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism III: Nursing Management
Peripheral Artery Disease III: Interprofessional Care

